BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...participation from existing investors including Menlo Ventures, Samsara Biocapital, Illumina Ventures, AV8 Ventures and Windham Venture Partners...
...$5.5 million seed financing led by Menlo Ventures and including Samsara BioCapital, Illumina Ventures, Windham Venture Partners...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...which also saw participation from Deerfield and existing investors including Goldman Sachs, Breyer Capital and Healthcare Venture Partners...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...INDs could be filed as soon as 2022. Backed by an investor syndicate led by Arch Venture Partners...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...total funding to about $750 million.GV, Arch Venture Partners...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

Editas Medicine Inc. (NASDAQ:EDIT) said CSO Charles Albright will depart Jan. 15 to pursue another opportunity. A search is under way to find a successor. Shares of the genome editing company fell 15% Monday to...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...by RA Capital Management and Vivo Capital; Foresite Capital, APlus Partners, Quan Capital and Qiming Venture Partners...
...Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA Capital Management Vivo Capital Foresite Capital Qiming Venture Partners Carisma...
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...another undisclosed backer also participated, as did existing investors Lilly Asia Ventures, Temasek Holdings, Qiming Venture Partners...
...discover small molecules that target protein-protein interfaces. Also investing were Eventide Asset Management, New Leaf Venture Partners...
...million in series A cash from lead investors Cobro Ventures and Lightchain Capital, along with LifeSci Venture Partners...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...at the firm, is the newco’s president and co-founder. The start-up’s other investors are 8VC, Hatteras Venture Partners...
...collaborators: Duke UniversityCorporate partners: N/ANumber of employees: ~25Funds raised: over $50 millionInvestors: Newpath Partners, 8VC, Hatteras Venture Partners...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...Ventures and Lux Capital as well as Alexandria Ventures Investments, Gaingels, KB Investment, LifeForce Capital, LifeSci Venture Partners...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...CEO of Brii, told BioCentury. Brii was launched in 2018 with $260 million from Arch Venture Partners...
Items per page:
1 - 10 of 2827
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...participation from existing investors including Menlo Ventures, Samsara Biocapital, Illumina Ventures, AV8 Ventures and Windham Venture Partners...
...$5.5 million seed financing led by Menlo Ventures and including Samsara BioCapital, Illumina Ventures, Windham Venture Partners...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...which also saw participation from Deerfield and existing investors including Goldman Sachs, Breyer Capital and Healthcare Venture Partners...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...INDs could be filed as soon as 2022. Backed by an investor syndicate led by Arch Venture Partners...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...total funding to about $750 million.GV, Arch Venture Partners...
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

Editas Medicine Inc. (NASDAQ:EDIT) said CSO Charles Albright will depart Jan. 15 to pursue another opportunity. A search is under way to find a successor. Shares of the genome editing company fell 15% Monday to...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...by RA Capital Management and Vivo Capital; Foresite Capital, APlus Partners, Quan Capital and Qiming Venture Partners...
...Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin Capital Woodline Partners Logos Capital Janus Henderson Investors Atlas Venture Abingworth Kira Pharmaceuticals RA Capital Management Vivo Capital Foresite Capital Qiming Venture Partners Carisma...
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...another undisclosed backer also participated, as did existing investors Lilly Asia Ventures, Temasek Holdings, Qiming Venture Partners...
...discover small molecules that target protein-protein interfaces. Also investing were Eventide Asset Management, New Leaf Venture Partners...
...million in series A cash from lead investors Cobro Ventures and Lightchain Capital, along with LifeSci Venture Partners...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...at the firm, is the newco’s president and co-founder. The start-up’s other investors are 8VC, Hatteras Venture Partners...
...collaborators: Duke UniversityCorporate partners: N/ANumber of employees: ~25Funds raised: over $50 millionInvestors: Newpath Partners, 8VC, Hatteras Venture Partners...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...Ventures and Lux Capital as well as Alexandria Ventures Investments, Gaingels, KB Investment, LifeForce Capital, LifeSci Venture Partners...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...CEO of Brii, told BioCentury. Brii was launched in 2018 with $260 million from Arch Venture Partners...
Items per page:
1 - 10 of 2827